ImageneBio, Inc. (IMA): restructuring charge — Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options

ImageneBio, Inc.

Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.
Reducing workforce by ~53% (18 employees); expected ~16 FTE remaining; cash costs ~$1.2M in Q2 2024.
Continuing IK-595 (MEK-RAF glue) Phase 1; >80% pERK inhibition at 4h, >60% at 24h; dose escalation ongoing.
Cash, equivalents and marketable securities $157.3M as of March 31, 2024.
Board authorized exploration of strategic alternatives including acquisition, merger, sale, or partnership.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ImageneBio, Inc. announced a restructuring with charges of approximately $1.2 million in cash expenditures affecting company-wide (clinical programs IK-930 and IK-595) (approximately 53%).

Type: restructuring
Charge: approximately $1.2 million in cash expenditures
Affected area: company-wide (clinical programs IK-930 and IK-595)
Headcount: approximately 53%

Exact text from the filing

the Restructuring Plan during the three months ended June 30, 2024 related to employee severance and related termination benefits, which are expected to result in approximately $1.2 million in cash expenditures. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-148112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.